Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer
Executive Summary
Emerging standards for regulatory use of RWE should resist the temptation to impose the standards and expectations of randomized clinical trials to a fundamentally different kind of evidence, Dreyer cautions.
You may also be interested in...
Clinical Study Report Release Could Compromise Patient Privacy, Groups Say
US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.
Real-World Reluctance? Despite Guidance, Drug Developers Wary Of RWE-Based Trials
Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will be accepted, US and other regulators are encouraging drug developers to take a chance – and some have taken on the challenge.
Real-World Evidence: Is Adoption In Latin America Possible?
Pfizer's Esther Avila says it will take a collaborative effort between industry and drug regulators across Latin America to spur adoption of real-world evidence in the region.